Physician profile
Daniel Mark Begel
NPI 1376609149
$5,235.42
in general payments reported to CMS, 2019-2025
12 companies · $809 in 2025
The $809 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $207 · 2021: $570 · 2022: $1,444 · 2023: $698 · 2024: $512 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.33 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,474.08 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,124.40 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $610.59 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $553.27 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $542.39 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $255.90 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $228.74 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Lundbeck LLC | $170.21 | 2021-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $84.63 | 2024-2025 | Cobenfy |
| Abbvie INC. | $80.02 | 2021-2025 | |
| Harmony Biosciences LLC | $65.17 | 2022-2023 | Wakix |
| Indivior INC. | $46.02 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Begel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.